Romanian pharmaceutical producer Antibiotice Ia\u0219i (BVB: ATB) announced that it secured its fifth consecutive contract with the United Kingdom’s National Health Service (NHS), significantly increasing its presence in the British market for injectable beta-lactam antibiotics.<\/p>\n
The agreement involves the supply of seven million vials of five types of sterile injectable penicillins to UK hospitals over a two-year period. These antibiotics are among the most widely prescribed medicines in the country.\u00a0<\/p>\n
Following the latest tender, Antibiotice expects to raise its UK market share for this category to 43%, up from 35% in 2021, positioning the company among Europe’s leading producers of sterile injectable penicillins.<\/p>\n
The NHS contract is highly competitive, with participation from major manufacturers across Europe and India. Antibiotice’s growing presence reflects the company’s capacity and consistency in supplying essential medicines to high-standard healthcare systems.<\/p>\n
In addition to its success in the UK, Antibiotice has recently expanded into other key European markets. The company won a public tender in Italy to supply approximately 400,000 vials of antibiotics annually, projecting a 40% market share for the targeted molecule segment.<\/p>\n
This year, Antibiotice will also enter Germany – the European Union’s largest pharmaceutical market – by supplying sterile injectable antibiotics. The company targets annual sales of 2.5 million vials in Germany, with hospital deliveries expected to begin in the fourth quarter of 2025.<\/p>\n
Commercial negotiations are also ongoing in Spain, Poland, Hungary, the Czech Republic, and Slovakia, where Antibiotice aims to launch products that are already authorized.\u00a0<\/p>\n
Efforts are also underway to expand into new markets, including Croatia, France, and Austria.<\/p>\n
iulian@romania-insider.com<\/em><\/p>\n (Photo source: Antibiotice.ro)<\/em><\/p>","protected":false},"excerpt":{"rendered":" Romanian pharmaceutical producer Antibiotice Ia\u0219i (BVB: ATB) announced that it secured its fifth consecutive contract with the United Kingdom’s National Health Service (NHS), significantly increasing its presence in the British market for injectable beta-lactam antibiotics. The agreement involves the supply of seven million vials of five types of sterile injectable penicillins to UK hospitals over […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-5361","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/ofero.news\/index.php?rest_route=\/wp\/v2\/posts\/5361","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ofero.news\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ofero.news\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/ofero.news\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5361"}],"version-history":[{"count":0,"href":"https:\/\/ofero.news\/index.php?rest_route=\/wp\/v2\/posts\/5361\/revisions"}],"wp:attachment":[{"href":"https:\/\/ofero.news\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5361"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ofero.news\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5361"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ofero.news\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5361"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}